The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.
Company news: Roche, MRM, McKesson
September 20, 2012
6:06 pm
Roche closes an R&D deal for NYC, MRM gets a new address and Arizona’s AG is suing McKesson.
Representatives from four states and the District of Columbia are asking Gilead to keep HIV drugs prices in check. The letter is a prelude to the FDA’s August 27 review of the Quad pill.
Sanofi’s talking allergy device an answer to Dey’s EpiPen
The drugmaker’s new auto-injecting epinephrine pen provides verbal cues during emergency allergic situations. It’s the latest entry in a competitive market.
Company news: Corcept Therapeutics and Daiichi Sankyo
March 23, 2012
2:35 pm
Corcept Therapeutics said its Cushing’s syndrome drug will be launched three weeks earlier than expected.
In the long run, reforms mean less risk, lower rewards for pharmas
In broad strokes, the healthcare reform bill that the president signed this noon holds much the same promise for pharmas as an SSRI does for depression or bipolar patients: less high highs, less low lows, more certainty and stability.
Aging Committee raps pharma on brand drug price hikes
Armed with AARP and Kaiser Family research, members of the Senate Special Committee on Aging asked panelists why brand drug prices in the US continue to increase, while other countries pay half as much for the same products.
A Government Accountability Office study found “extraordinary price increases” in 416 branded drug products (across 321 brands) between 2000 and 2008. That’s about half of one percent of all branded drug products.
Clinton vows price controls, generic biologics in healthcare plan
September 17, 2007
4:00 am
Sen. Hillary Clinton unveiled her healthcare plan, promising to cover all Americans if elected president – and taking a few swipes at the pharmaceutical and insurance industries.